Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV

The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.

Appendix B: Panel Roster and Financial Disclosures


Last Updated: November 1, 2012; Last Reviewed: November 1, 2012

Disseminated Mycobacterium avium Complex Disease
Member Financial Disclosure
Company Relationship
Cohn, David University of Colorado School of Medicine None N/A
Currier, Judith
University of California, Los Angeles
Achillion DSMB Member
EMD Seronon Advisory Board
Gilead Consultant
GlaxoSmithKline Honoraria
Janssen-Cilag Honoraria, Travel Support
Koronis DSMB Member
Merck Advisory Board, Research Support
Pfizer Advisory Board
Schering-Plough Research Support
Tibotec Advisory Support, Research Support, Travel Support
Dorman, Susan Johns Hopkins University Bill and Melinda Gates Foundation Research Support
FDA Research Support
NIH Research Support
Gordin, Fred*
Veterans Affairs Medical Center; Washington , DC
None N/A
Horsburgh, C. Robert Boston University Bill and Melinda Gates Foundation Travel Support
CDC Research Support
Medical Research Council (UK) Travel Support
NIH Research Support
* Group lead

Note: Members were asked to disclose all relationships from 24 months before the writing panel convened. The period of reporting was from June 1, 2008, through November 1, 2012.

Download Guidelines